Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind crossover pharmacodynamic comparison of JW2202 dry powder inhaler versus glycopyrronium bromide + formoterol fumarate inhalation aerosol in COPD
CTR20250858Phase 2Suspended
- Sponsor
- Shandong Jianwei Pharmaceutical
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate, glycopyrronium, formoterol in chronic obstructive pulmonary disease (COPD), sponsored by Shandong Jianwei Pharmaceutical. Started Mar 2025; status: suspended.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoateglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20250858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250858.